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Abstract: Statins (3-hydroxy-3-methyl glutaryl coenzyme A [HMG-CoA] reductase inhibitors) 
are the most commonly used lipid-lowering drugs. Their main lipid-lowering effect is achieved 
by an increase in the expression of low-density lipoprotein cholesterol receptors associated with 
inhibition of cholesterol synthesis through inhibition of HMG-CoA reductase – the first and 
rate-limiting step in cholesterol synthesis. However, beyond cholesterol synthesis inhibition, 
inhibition of the HMG-CoA reductase affects as well the synthesis of other molecules with 
significant roles in different, yet often intercalating, metabolic pathways. On this basis, and 
supported by an increasing series of advocating epidemiological and experimental data, an 
extended dialogue has been established over the last few years regarding the nonlipid or 
“pleiotropic” actions of statins.
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Introduction
Statins are the most widely prescribed lipid-lowering drugs worldwide. They 
have been persistently shown to decrease serum low-density lipoprotein (LDL) 
cholesterol (by as much as 70%), total cholesterol and serum triglycerides and 
increase serum high-density lipoprotein (HDL) cholesterol. Statins target mainly 
hepatocytes and inhibit 3-hydroxy-3-methyl glutaryl coenzyme A (HMG-CoA) 
reductase, the enzyme that converts HMG-CoA into mevalonic acid, a cholesterol 
precursor. The mevalonate pathway then branches out before the synthesis of 
squalene and cholesterol (Figure 1). Other biologically important products are 
dolichols, which are involved in lipoprotein synthesis, ubiquinone, and the 
isoprenoids, farnesyl-pyrophosphate (PP) and geranylgeranyl-PP.1 Isoprenoids 
can be covalently bound to proteins, a process termed prenylation, and play 
an important role in the post-translational modification of regulatory proteins, 
such as G proteins, Ras, Rho, and Rab, that influence the polymerization, the 
membrane anchoring and intracellular trafficking and thus the biologic activity 
of these proteins.2
Large-scale epidemiologic studies, such as 4S,3 WOSCOPS,4 CARE,5 LIPID,6 
AFCAPS/TexCAPS,7 REVERSAL,8 AVERT,9 PROVE IT-TIMI 22,10 HPS,11 and 
ASCOT-LLA12 have provided solid data showing statins’ preventive effects on the 
progression of atherosclerosis and its clinical sequelae. The beneficial effects of statins 
on vascular clinical events had been attributed solely to their lipid-lowering action 
until recently. However, the results from these and several other recent clinical studies Drug Design, Development and Therapy 2009:3 192
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have been surprising and intriguing. In particular, statins’ 
efficacy even in patients with normal cholesterol levels,11,13 
as well as the rapidity and magnitude of their action have 
suggested that other factors are at play. Careful comparison 
of the cardiovascular event rates in patients on statins 
with the rates expected for those with similar lipid levels 
from epidemiological data has shown that statin treatment 
decreases the rate below that expected.4,14 Furthermore, 
although some regression in lesion size has been achieved 
with statins,15 it is not of such a magnitude that could explain 
their clinical efficacy. The increasing perception of the 
inflammatory pathology of atherosclerosis has led to further 
research for the multipotentiality of these drugs. The term 
“pleiotropic effects” signifies effects of statins other than 
cholesterol-lowering, though for many of these effects it 
has not been proved that they are really independent of their 
hypocholesterolemic action.
Mechanisms of action
Direct lipid actions
inhibition of HMG-CoA reductase
Statins target hepatocytes and inhibit HMG-CoA reductase, 
the enzyme that converts HMG-CoA into mevalonic acid, 
a cholesterol precursor (Figure 1). Through the inhibition 
of this rate-limiting step in cholesterol synthesis statins 
achieve an increase in the expression of LDL cholesterol 
receptors, which results in increased take up by hepatocytes 
of LDL cholesterol from the circulation and a decrease in 
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Figure 1 The mevalonate pathway.
Abbreviations:   Acetyl-CoA, acetyl-coenzyme A; HMG-CoA, 3-hydroxy-3-methyl glutaryl coenzyme A; PP, pyrophosphate.Drug Design, Development and Therapy 2009:3 193
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plasma LDL cholesterol level. Statins do not simply exert a 
competitive action against the normal substrate in the enzyme 
active site; instead, they bind reversibly HMG-CoA reductase 
and result in a conformational change in the enzyme active 
site, preventing HMG-CoA reductase from attaining a 
functional structure. The resultant increase in hepatic cell 
LDL receptors determines the reduction of circulating LDL 
and of its precursors (intermediate-density [IDL] and very 
low-density [VLDL] lipoproteins).16 Statins’ efficacy in 
the reduction of triglyceride concentration parallels LDL 
cholesterol reduction.17 HMG-CoA reductase inhibition 
by statins results also in the inhibition of hepatic synthesis 
of apolipoprotein B-100 and, thus, in the reduction of the 
synthesis and secretion of triglyceride rich lipoproteins, as 
well as in an increase in the production of receptors for apoli-
poprotein B. Statins have only modest effect on HDL increase 
and no influence on the concentration of lipoproteins.
reduction of LDL susceptibility towards oxidation
At least five mechanisms have been proposed to explain 
statins’ antioxidant properties:18 (a) the reduced lipoprotein 
cholesterol and reduced level of oxidation substrate, as a 
result of their hypocholesterolemic effect; (b) the inhibition of 
the generation of superoxide by macrophages, which results 
in the decrease of cell oxygen production. The attenuation of 
the formation of superoxide anion in endothelial cells is also 
achieved by statins by preventing the prenylation of p21 Rac 
protein; (c) the preservation of the activity of the endogenous 
antioxidant system, like superoxide dismutase; (d) the binding 
of statins to phospholipids on the surface of lipoproteins 
(fluvastatin and lovastatin bind to LDL phospholipids) 
preventing the diffusion towards the lipoprotein core of free 
radicals generated during oxidative stress; and (e) the potent 
antioxidative potential of the metabolites (ie, atorvastatin and 
fluvastatin metabolites).
inhibition of the expression  
of type A scavenger receptor
The inhibition of the expression of type A scavenger recep-
tor in THP-1 cells and in human monocytes19 decrease the 
receptor-mediated degradation of oxidized LDL (oxLDL). 
Statins also reduce mRNA level and CD36 expression on 
the cell surface, as well as LDL binding to human U937 
monocytes.20
intracellular signaling pathways
Several of the pleiotropic effects of statins, which affect 
endothelial function and redox equilibrium as well, have 
been attributed to the prenylation of regulatory proteins, 
such as the G proteins, and the enzymes involved in this 
prenylation have been proposed as potential targets for 
therapeutic intervention.21 Prenylated proteins may interact 
with specific membrane-bound receptor proteins and 
hence prenylation mediates protein–protein interactions. 
The complex process of cell signaling is very important 
for intercellular communication. Extracellular signaling 
molecules, which are water-soluble and have high molecular 
weight, need to bind to specific receptors on the cell surface, 
which transduce the extracellular signals into the cell by 
intracellular signaling pathways. Many intracellular signaling 
molecules are prenylated proteins. The specific receptors on 
the cell surface are associated with trimeric G protein, or 
have Ser/Thr/Tyr kinases activities. The trimeric G protein 
has a geranylgeranylated subunit (gamma), allowing this 
signaling protein to be inserted in the cell membrane near 
specific membrane receptors and to receive extracellular 
signals, which are then transferred to the secondary signaling 
molecules in the cell. Another important class of prenylated 
signaling molecules are the components of Ras family, which 
are farnesylated and intermediate the Ser/Thr/Tyr kinases 
activities of membrane receptors from the cell surface. 
The small monomeric G proteins, such as Rho, are also 
regulated by prenylation. It has been known for some time 
that Rho is a regulator of actin-containing stress fibers of the 
cytoskeleton22 and more recently of focal adhesion sites, a 
cell membrane component connected to stress fibers. These 
sites are foci where integrins congregate and through which a 
cell makes adhesive contacts with extracellular components, 
either other cells or extracellular matrix proteins. They also 
contain the proteins focal adhesion kinase (pp125 FAK), 
p130, and paxillin.23 Recent evidence confirmed the 
essential role of Rho in the assembly of the focal adhesion 
sites.24 Other G protein pathways may also be involved 
in focal adhesion formation, as the lipoxygenase-derived 
arachidonic acid metabolite 5-hydroxyeicosatetraenoic 
acid can activate neutrophil self-adhesion via the G protein 
pathway Raf-1/Mek/ Erk.25 In the case of the β1 integrins, 
which are involved in leukocyte adhesion to extracellular 
matrix, there is direct evidence that adhesion of U937 cells 
involves geranylgeranylated signaling proteins.26
Despite the fact that several effects of statins were 
shown to be independent of cholesterol lowering in vitro, 
extensive evidence links hypercholesterolemia in vivo with 
increased lipid peroxidation and increased oxidative stress,27 
and increased oxygen radical formation accompanying 
hypercholesterolemia influences many of the same factors 
that are modulated by statins via inhibition of prenylation. Drug Design, Development and Therapy 2009:3 194
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It is well established that multiple signaling pathways 
regulating the expression of atherogenic genes are oxidation-
sensitive, either because oxLDL activates them by binding 
to cell surface receptors or because increased extracellular 
lipid oxidation causes a shift in the intracellular redox 
balance.28 Among the many oxidation-sensitive pathways 
that affect cell growth, secretory activity, and death, three are 
particularly relevant in inflammation and atherogenesis. The 
first of these is nuclear factor-κB (NFκB), which regulates 
adhesion molecules and growth factors, including vascular 
cell adhesion molecule-1 (VCAM-1), intercellular adhesion 
molecule-1 (ICAM-1), and monocyte chemoattractant 
protein-1 (MCP-1), important contributors to monocyte and 
T cell recruitment into the arterial intima.29 The second is the 
apoptotic signaling pathway that is activated through Fas/FasL 
and tumor necrosis factor (TNF) receptors and regulates the 
expression of caspases and other effectors of apoptosis.30 
The third oxidation-sensitive pathway is the peroxisome 
proliferators-activated receptor γ (PPARγ) pathway. PPARγ 
is a nuclear receptor that regulates fat cell development and 
glucose. It is also highly expressed in macrophage/foam 
cells of atherosclerotic lesions. Activation of PPARγ by 
oxLDL or synthetic ligands upregulates the expression of the 
ABC-A1 transporter involved in reverse cholesterol transport 
from peripheral cells, but it also downregulates a number of 
pro-inflammatory factors, including TNFα, interleukin-1α 
(IL-1α), IL-6, the inducible nitric oxide synthase (iNOS), 
and gelatinase B, one of the metalloproteinases thought to 
promote plaque rupture.31 Therefore, many of the factors 
which hypercholesterolemia and its associated oxygen radical 
formation affect are modulated by statins via inhibition of 
prenylation. For example, the conversion of NO into the 
less active peroxynitrate is the mechanism through which 
hypercholesterolemia induced LDL oxidation interferes 
with NO-mediated vasodilatation. Statins act on this site by 
decreasing the activity of NAD(P)H oxidase and therefore 
by increasing endothelial NO production and decreasing the 
production of reactive oxygen species (ROS), reducing thus 
both LDL oxidation and intracellular oxidative stress.32
Pleiotropic effects
Recent evidence revealed a multitude of actions of statins, 
other than lipid-lowering, on different types of cells, which 
have been addressed with the term “pleiotropic” and are 
predominantly vasoprotective. These include inhibition 
of smooth muscle cell growth, inhibition of neointima 
formation, induction of apoptosis in smooth muscle cells, 
reduction of leukocyte adhesion to and transmigration 
through endothelial cells, induction of endothelial nitric oxide 
synthase, inhibition of endothelin and MCP-1 expression 
in endothelial cells, inhibition of MCP-1, tissue factor 
and matrix metalloprotease-9 expression in macrophages. 
Figure 2 summarizes the mechanisms through which statins 
exert their vasoprotective effects.
Effects on endothelial dysfunction and inflammation
Atherosclerosis is a complex inflammatory process 
characterized by the presence of monocytes, macrophages, 
and T lymphocytes in the atheroma.33 Endothelial dysfunction 
is one of the earliest manifestations of atherosclerosis, 
occurring well before the presence of any angiographic 
evidence of disease.34 Studies in animals and humans have 
shown that the combination of hemodynamic strain and 
the accumulation of lipids may initiate an inflammatory 
process in the artery. Activated endothelial cells express 
several types of leukocyte adhesion molecules, which cause 
blood cells rolling along the vascular surface to adhere 
at the site of activation.35 An important characteristic of 
endothelial dysfunction is the paradoxical vasoconstriction 
caused by acetylcholine because of the impaired synthesis, 
release, and activity of endothelium-derived nitric oxide 
(NO). Statins reverse endothelial dysfunction through the 
reduction of both extracellular LDL oxidation (by reducing 
substrate availability) and intracellular oxidative stress (by 
cholesterol-independent effects on NO and, indirectly, by 
reducing oxLDL). Geranyl-geranylation of the GTP-inding 
protein Rho decreases endothelial cell nitric oxide synthase 
(eNOS) expression and inhibits nitric oxide-induced vascular 
relaxation. By blocking synthesis of geranyl-geranyl-PP, 
statins decrease geranylation of Rho and upregulate eNOS.37,38 
Nitric oxide generation in endothelial cells is also promoted 
by another mechanism. Statins activate the protein kinase 
Akt/PKB, which results in enhanced phosphorylation (activa-
tion) of its natural substrate, eNOS.38 Regarding the effects 
of statins on Akt activation and nitric oxide, Laufs and col-
leagues39 showed that statins prevent the hypoxia-induced 
downregulation of NOS 3 in human endothelial cells via 
inhibition of mevalonate synthesis. Furthermore, in human, 
increased circulating NO was found in response to fluvastatin 
treatment, which correlated with decreased circulating soluble 
P-selectin and ICAM-1 levels.40 Kureishi and colleagues38 
found that simvastatin activates the signaling molecule Akt in 
human umbilical vein endothelial cells (HUVEC), an effect 
requiring phosphatidylinositol 3-kinase (PI3-kinase), which 
indeed is normally the upstream activator of Akt, and being 
inhibited by the specific PI3-kinase inhibitor wortmannin. Drug Design, Development and Therapy 2009:3 195
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Normally, PI3-kinase activity is suppressed by mevalonate, 
so that the decrease in mevalonate concentration caused 
by statin action would be expected to increase PI3-kinase 
activity. Akt itself undergoes phosphorylation by PI3-kinase, 
thereby phosphorylating NOS 3 (one of several substrates for 
Akt) and thus increasing NO production. Enhanced NOS 3 
activity, and hence NO production, will give rise not only 
to vasodilatation but also to other potentially beneficial and 
vasoprotective effects: inhibition of atherogenesis, inhibi-
tion of platelet activation and aggregation, attenuation of 
endothelial cell apoptosis, and promotion of angiogenesis. 
Increased formation of NO promotes arterial vasodilatation 
and inhibits atherogenesis.41 NO is therefore emerging as a 
prime target for pharmacologic intervention.42 Resistance to 
the inhibitory effect of oxLDL on NOS 3 activity has also 
been elicited by statin treatment in vitro. By contrast with 
the induction of NOS 3 by statins, which has a generally 
beneficial action, lovastatin inhibited NOS 2 (the inducible 
isoform of NOS) expression in rat astrocytes, microglia, 
and macrophages.43 This may be advantageous, as the large 
quantities of NO generated by NOS 2 may not be as benign as 
the smaller amounts generated through NOS 3. In addition to 
preventing the Rho-mediated downregulation of eNOS, other 
effects of statins have been linked to geranyl-geranylation, 
such as inhibition of proliferation and induction of apoptosis 
in SMCs,44 inhibition of integrin-dependent leukocyte adhe-
sion and increased fibrinolytic activity.45 The observation of 
some of these effects, eg, improved vascular function,46 in 
the absence of hypercholesterolemia supports the notion that 
they are cholesterol-independent. Unequivocal evidence that 
many of the above effects are due to protein prenylation has 
been provided by the fact that they are reversible by addi-
tion of geranylgeranyl-PP (or farnesyl-PP), which does not 
restore cholesterol synthesis, but not by addition of squalene 
or cholesterol.
Recent evidence suggests that statins possess anti-
inflammatory properties because of their ability to reduce the 
number of inflammatory cells in atherosclerotic plaques.47 
The mechanisms have yet to be fully elucidated but seem to 
involve inhibition of adhesion molecules expression, reduction 
of leukocyte adhesion,48 as well as inhibition of inflammatory 
and chemotactic cytokine production. Lovastatin and sim-
vastatin have been found to reduce the production of MCP-1 
in human peripheral blood mononuclear cells or endothelial 
cells following exposure to lipopolysaccharide (endotoxin), 
other bacterial products, or the inflammatory cytokine IL-1. 
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Likewise, they reduced the exudates content of MCP-1 and 
the degree of leukocyte accumulation in a mouse air-pouch 
inflammation model.49 The expression of MCP-1 in both 
endothelial cells and monocyte-derived macrophages 
of atherosclerotic plaques is believed to be important in 
mediating monocyte chemotaxis and hence in stimulating 
atherogenesis. Indeed, it has been found that statins reduce 
the expression of adhesion molecules on leukocytes,50 
inhibit leukocyte-endothelium interactions,51 and reduce 
inflammatory cell number within atherosclerotic plaques.52 
Xenos and colleagues53 have shown in human iliac artery 
endothelial cell cultures that fluvastatin caused a substantial 
reduction in ICAM-1 expression, through the upregulation 
of eNOS and AMP kinase. Cicha and colleagues54 in their 
study on HUVEC cultures found that statins reversed the 
shear stress-induced expression of adhesion molecules on 
endothelial cells. Moreover, Lin and colleagues55 found in 
human aortic endothelial cell cultures that statins caused a 
similar reversion of homocystein-induced VCAM-1 expres-
sion upregulation. Interestingly, Liang and colleagues56 
found in HUVEC cultures that simvastatin reduced VCAM-1 
expression on endothelial cells as well as the adhesiveness 
of monocytes, through inhibition of NF-κΒ activation by 
C-reactive protein (CRP).
Integrins are activated through a conformational change 
of their molecule and it has been suggested recently that 
the principal regulation of integrins in vivo is by receptor 
clustering into adhesion complexes.57 Rho geranylgeranyl-
ation by HMG-CoA reductase products is likely to play a 
crucial role in this procedure.58 Cerivastatin was shown by 
Yoshida and colleagues59 to reduce human monocyte cell 
line adhesion to endothelial cells under physiological flow 
conditions via RhoA-dependent mechanisms. Similarly, 
atorvastatin was found to reduce the adhesion of U937 cells 
to HUVEC and to decrease RhoA and FAK activation also in 
those cells.60 It is likely that HMG-CoA reductase inhibitors 
can inhibit focal adhesion complex formation and thereby 
inhibit leukocyte adhesion. In the absence of an activating 
signal, the β2 integrin leukocyte function antigen-1 (LFA-1) 
does not associate with lipid rafts. After its activation in 
T-lymphocytes, LFA-1 is mobilized to the lipid raft domains. 
The association between LFA-1 and lipid rafts is required 
for LFA-1-dependent adhesion to occur, and similar results 
were obtained with α4β1 integrin.61 The recent work of Lum 
and colleagues62 provided direct evidence of the involvement 
of these events in leukocyte-endothelial adhesion. RhoA 
molecule, beyond its involvement in these events of integrin 
activation that take place in leukocytes, with particular 
relevance to atherosclerosis, it is also involved in endothelial 
cells in creating receptor clusters, which allow adhesion 
to monocytes. Association with the actin cytoskeleton 
is required, but the formation of stress fibers is not.63 
Monocyte adhesion and spreading on human endothelial 
cells is dependent on Rho regulated receptor coupling in 
the latter. Therefore, both types of cell involved in the 
monocyte-endothelial interaction could possibly be affected 
by statin-mediated modification of Rho signaling, though 
evidence from cellular adhesion studies suggests that it is 
mainly the monocyte that is affected in vivo. Surprisingly, 
lovastatin, simvastatin, and other statins were found capable 
of binding to a novel site on the I-domain of LFA-1.64 This 
domain is probably involved in activation changes that allow 
binding to ICAM-1. Interestingly, even the lactone forms 
of the statins were capable of binding despite having no 
activity against HMG-CoA reductase. This binding inhibits 
the adhesive activity of LFA-1 while, a novel high affinity 
statin- related compound, LFA703, was found to have 
powerful anti-inflammatory activity. However, this field 
remains controversial, as long as statin-LFA-1 interaction 
was not confirmed by others.
Further parallel evidence was obtained from the 
suppression of IL-8 and MCP-1 production by cerivastatin 
in macrophages.65,66 Similarly, in endothelial cells, the 
more lipophilic statins upregulate PPARγ, resulting in 
decreased expression of IL-1, IL-6, and cyclooxygenase 
(COX)-2.67 The decrease in IL-6 production could provide 
an explanation for the decreased production of CRP observed 
in vivo in patients on statin therapy, as IL-6 is the principal 
inducer of its synthesis in the liver.68 More recently, it was 
shown in an in vitro system that human adipocytes can 
release CRP under inflammatory conditions and that this 
phenomenon may be modulated by statin treatment,69 a find-
ing which might explain in part the beneficial cardiovascular 
effects of these drugs.70 Furthermore, recently it was found 
that statins reduce IL-6 induced CRP directly in hepatocytes 
via inhibition of protein geranylgeranylation and of the 
phsophorylation of the transcription factor STAT3.71,72 Other 
probable beneficial effects of statins include an increase 
in the number and mobilization of circulating endothelial 
progenitor cells (EPCs), which are cell with reparative 
action on sites of ischemic injury, the inhibition of the 
migration and proliferation and the induction of apoptosis 
of vascular smooth muscle cells (SMCs)73 and the inhibition 
of leukocyte–endothelial cell interactions.74 Statin treatment 
has also been found to reduce effectively experimental 
atherosclerosis as well.75–77Drug Design, Development and Therapy 2009:3 197
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effects on immune responses
Although strictly speaking not yet proven, there is substantial 
evidence that statins may modulate immune responses. These 
include effects on the intimal recruitment, differentiation, 
proliferation, and secretory activity of a number of immune 
cells, mainly monocyte/macrophages and T cells.78–82 
Recently, statins were found to inhibit the expression of 
class II major histocompatibility antigens (MHC-II) on human 
macrophages, endothelial cells and SMCs stimulated by inter-
feron γ (IFN-γ).83,84 Precise regulation of MHC class II gene 
expression plays a pivotal role in the control of the immune 
response especially after transplantation. The expression of 
MHC-II on the surface of antigen-presenting cells together with 
processed antigens and cellular cofactors results in activation 
of the T cell receptor. Statins’ effect on the expression of 
MHC-II is exerted by both lipophilic and hydrophilic statins 
at nanomolar to micromolar concentrations, but it is limited to 
antigen-presenting cells requiring co-stimulation by IFN-γ, an 
effect which is dose-dependent for both MHC class II protein 
as well as mRNA. Whereas a limited number of specialized 
antigen-presenting cells express MHC class II constitutively, 
numerous other cells become MHC class II-positive upon 
induction with IFN-γ.85 This means that professional 
antigen-presenting cells constitutively expressing MHC-II, 
eg, B cells and dendritic cells are not affected. This complex 
regulation is under the control of the class II transactivator 
CIITA. Statins were found to inhibit promoter IV of the 
MHC-II transactivator CIITA, which regulates transcription 
of MHC-II and thus synthesis of the MHC-II protein.86,87 In 
contrast, statins did not affect the expression of MHC class I, 
pointing to specific actions in the MHC class II signaling 
cascade. This discovery has been proposed88 to provide a firm 
scientific rationale to recommend the use of this drug as an 
immunosuppressor. The reduction of MHC-II molecules on 
the vast majority of arterial cells leads to a reduction of  T cell 
proliferation and differentiation. Mixed lymphocyte reactions 
showed that statin treatment of endothelial cells and SMCs 
indeed reduced T cell proliferation and IL-2 release. These 
in vitro data provide evidence that the overall effect of reduced 
activation and proliferation of  T cells, mostly the Th1 cell 
subpopulation which is the one that secretes cytokines such as 
IFN-γ that promote inflammation, in the arterial wall, would 
likely be beneficial.
In another study, statins were found to exert a selective 
blocking of the β2 integrin LFA-1.89 LFA-1, also known 
as CD11a/CD18, is expressed on the surface of leukocytes 
and, when activated, binds to ICAM-1. In addition to its 
role in leukocyte adhesion and extravasation, LFA-1 is a 
co-stimulator of T cells. At least one clinically used statin, 
lovastatin, as well as several modified statin compounds 
subsequently developed, bound selectively to a novel site 
of LFA-1 and prevented LFA-1–mediated adhesion and 
lymphocyte co-stimulation. This effect was unrelated to the 
statins’ inhibition of HMG-CoA.
Antioxidant effects
Another class of actions for statins and a potential mecha-
nism by which statins may improve endothelial function is 
through their antioxidant effects. In this regard, a recent study 
showed that pravastatin therapy caused an early significant 
decrease in serum malondialdehyde concentration, an index 
of lipid peroxidation and plaque instability, and increase in 
flow-mediated dilation of the brachial artery, before any 
substantial reduction in blood lipid levels, in 37 patients with 
unstable angina.90 These findings suggest that pravastatin 
exerts pleiotropic effects on endothelial dysfunction during 
the early phase of the acute coronary syndrome, that are 
independent of the degree of plasma cholesterol lowering;91 
however, it has never been unequivocally demonstrated 
in humans that prolonged statin treatment exerts effects 
independent of LDL cholesterol lowering because the use 
of statins always resulted in reduced LDL cholesterol levels. 
In a recent study, Pretnar-Oblak and colleagues92 found a 
significant improvement of the cerebrovascular reactivity 
to intravenous application of l-arginine, a perceived index 
of cerebral endothelial function, as well as flow-mediated 
dilatation of the brachial artery, after a three-month treatment 
with atorvastatin in patients with lacunar cerebral infarctions, 
a state of endothelial impairment. In their elegant study, 
Landmesser and colleagues93 showed that despite the similar 
reduction in LDL cholesterol levels caused by simvastatin 
and ezetimibe, a novel cholesterol absorption inhibitor, 
only simvastatin resulted in beneficial effects on endothelial 
function.
effects on plaque stability
It is now established that atherosclerotic plaques are hetero-
geneous and vary in their tendency to undergo thrombosis 
and the consequent acute clinical events. Plaques with a 
high degree of smooth muscle cell proliferation, giving rise 
to well-developed tough fibrous caps on the luminal side of 
the lesions, rarely are complicated by thrombosis and are 
termed stable plaques. On the other hand, lesions rich in 
inflammatory macrophages and lipid deposits are mechani-
cally weaker, as metalloproteinase enzymes from macro-
phages digest the extracellular matrix and weaken the wall. Drug Design, Development and Therapy 2009:3 198
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They frequently crack, so exposing circulating platelets to an 
abnormal vascular wall that rapidly induces activation and a 
thrombotic mass.94 These are unstable plaques, the inflamma-
tory nature of which is central to their clinically hazardous 
behavior. Coronary events are the result of unstable 
atherosclerotic lesion rupture and thrombus formation.95 High 
circulating cholesterol, apart from promoting atherogenesis, 
may also give rise to an increase in thrombogenesis through 
an increase in tissue factor expression.96 Fluvastatin has 
been shown to decrease this prothrombotic tendency with 
an associated reduction in tissue factor, and this may be 
partly through cholesterol lowering but also through non-
cholesterol-mediated actions, such as reduced prenylation of 
the Rho protein Cdc42. Statins influence plaque stability by 
preventing macrophage activation, reducing the uptake and 
endogenous synthesis of cholesterol and the production of 
metalloproteinases by macrophages.97 Metalloproteinases are 
the enzymes responsible for weakening the plaque’s fibrous 
cap, thereby increasing the risk of rupture. In addition, lipid 
lowering by statins contributes to stability by reducing plaque 
size, by modifying the physicochemical properties of the 
lipid core,98 by combined reduction in lipids, lipid oxidation, 
matrix-metalloproteinase-2, inflammation, and cell death, or 
by increases in tissue inhibitor of metalloproteinase-1 and 
collagen content.99
effects on thrombogenesis and thrombolysis
It is now established that atherosclerotic plaques are hetero-
geneous and vary in their tendency to undergo thrombosis and 
the consequent acute clinical events. Plaques rich in inflam-
matory macrophages and lipid deposits are mechanically 
weaker (“unstable plaques”), as metalloproteinase enzymes 
from macrophages digest the extracellular matrix and weaken 
the wall, they frequently crack, so exposing circulating 
platelets to an abnormal vascular wall that rapidly induces 
activation and a thrombotic mass. High circulating choles-
terol, beyond promoting atherogenesis, may also give rise to 
an increase in thrombogenesis through an increase in tissue 
factor expression, in platelet reactivity, in thromboxane A2 
(TXA2) synthesis, in platelet α2 adrenergic receptor density, in 
platelet cytosolic calcium, and changes in platelet membrane 
phospholipids and cholesterol. Platelets play a critical role in 
the development of acute coronary syndromes.102 Although 
the precise mechanisms involved are not fully understood, 
statins have been shown to influence platelet function,101 
probably through reduction in the production of TXA2, 
increased synthesis of prostacyclin,102 and modifications 
in the cholesterol content of platelet membranes. Notably, 
one of the well-characterized effects of endothelial NO is 
its inhibition of platelet aggregation. Thrombosis on mildly 
damaged swine arteries at high shear rate was reduced by 
half with atorvastatin.103 Likewise, blood from patients on 
statins showed significant reduction in platelet thrombus 
formation,104 and platelet-derived thrombin generation was 
decreased.105 Both lipid-lowering and nonlipid-related effects 
are likely to contribute, as patients with hypercholesterolemia 
have hyperreactive platelets, which would be normalized with 
lipid lowering.106 Furthermore, multiple other routes of action 
have been detailed.107 Hypercholesterolaemic patients also 
have increased circulating coagulation factors and increased 
soluble CD41 ligand, a cell-activating factor derived 
from activated platelets; these components are reduced 
by pravastatin or cerivastatin treatment.108 Mechanisms 
involved in the antithrombotic action of statins may include 
the augmented production of NO from endothelial cells, as 
described above. In addition, atorvastatin administered to 
mice was found to enhance platelet production of NO, and 
this was accompanied by a decrease in circulating markers 
of platelet activation,109 which is probably related to the 
reduction of geranylation of Rap1b, a protein involved in 
platelet aggregation.110,111 The effect of statins on other cells 
involved in thrombosis also appears to play a part. Human 
aortic smooth muscle cells in vitro were found to increase 
their expression of COX-2 and production of prostacyclin, a 
platelet inhibitory agent, under the influence of mevastatin or 
lovastatin.102 In addition, statins have been shown to mitigate 
platelet stimulation in a time- and dose-dependent manner, 
to decrease the prothrombin fragments F1+2 in plasma from 
patients with type 2 diabetes, independent of cholesterol 
levels, and to act as inhibitors of tissue factor-dependent 
thrombin generation.112 The authors of a recent study 
hypothesized that statins decrease the exocytosis of Weibel–
Palade bodies, which are endothelial cell granules whose 
contents promote thrombosis and vascular inflammation.113 
Simvastatin decreased thrombin-stimulated Weibel–Palade 
body exocytosis by 89%, in part by increasing the synthesis of 
NO, which induced s-nitrosylation of the n-ethylmaleimide-
sensitive factor, a critical regulator of exocytosis. Simvastatin 
treatment also decreased the myocardial infarct size by 58% 
in wild-type but not eNOS knockout mice. Furthermore, 
simvastatin decreased endothelial exocytosis and neutrophil 
infiltration into the ischemic reperfused myocardium, which 
was mediated in part by the P-selectin contained in the 
Weibel–Palade bodies. However, simvastatin did not affect 
the exocytosis and inflammation in the myocardial infarcts of 
eNOS knockout mice. Inhibition of endothelial exocytosis is Drug Design, Development and Therapy 2009:3 199
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a novel mechanism by which statin inhibitors reduce vascular 
inflammation, inhibit thrombosis, and protect the ischemic 
myocardium. Recently, an in vivo study investigated the 
effects of rosuvastatin on vascular remodeling and thrombo-
sis after arterial injury in apoE-/- mice. In the rosuvastatin 
treated mice, the size of the neointimal area and the severity 
of the luminal stenosis were significantly reduced, and these 
effects were independent of systemic lipid lowering.114
Furthermore, statins exert antithrombotic effects on 
monocytes through reduction of the synthesis of plasminogen 
activator inhibitor (PAI)-1, a change likely to result in 
enhanced fibrinolysis and thrombus dissolution.115,116 The 
same result may be achieved in another route in endothelial 
cells, as statins cause an increase in expression of tissue 
plasminogen activator (t-PA). Activation of the coagulation 
pathway may also be impeded, as tissue factor expression has 
been found to be prevented by statins in human endothelial 
cells.117 There is increasing evidence from in vitro studies that 
statins positively affect the fibrinolytic system of cultured 
smooth muscle cells as well as endothelial cells. In these 
studies a decrease in PAI-1 and an increase in t-PA were 
observed after co-treatment with statins in endothelial cells.118 
It seems likely that further pathways remain to be discovered. 
Remarkably, statins may have a direct influence on the coagu-
lation pathway itself, as patients treated with simvastatin 
were seen to have decreased rates of stimulated activation 
of fibrinogen, prothrombin, factor V, and factor XIII.119 
These changes did not relate to cholesterol lowering. Finally, 
initiation of thrombosis may be substantially inhibited by 
the stabilization of plaques by statin therapy. Furthermore, 
fluvastatin has been shown to decrease prothrombotic 
tendency with an associated reduction in tissue factor,121 
and this may be partly through cholesterol lowering but also 
through noncholesterol-mediated actions, such as reduced 
prenylation of the Rho protein Cdc42.
Clinical studies
Statin therapy has been shown to reduce cardiovascular risk 
even in patients without vascular disease.121 Large epidemio-
logic studies have shown that CRP is a predictor of cardiovas-
cular disease in the general population122–125 as well as special 
patient populations, such as patients with diabetes mellitus 
and patients with end-stage renal disease.126–129 Statin therapy 
lowers high sensitivity-CRP (hs-CRP) levels in patients with 
hypercholesterolemia.130 Long-term therapy with pravastatin 
in the Cholesterol and Recurrent Events (CARE) trial also 
reduced the levels of CRP,131 a change which was not found 
to correlate with the reduction in LDL cholesterol levels. 
The latter finding seems to be confirmed by recent trials, 
such as the PRINCE study.132 In the more recent JUPITER 
study,133 a four-year treatment with rosuvastatin resulted in 
considerable decrease in hs-CRP levels and cardiovascular 
morbidity in healthy adults without hyperlipidemia. However, 
any potential clinical benefits conferred by the lowering of 
hs-CRP levels are difficult to separate from those of the lipid-
lowering effects of statins without further clinical studies and, 
even in the JUPITER study in patients with no hyperlipidemia, 
hs-CRP lowering was escorted by a significant reduction in 
LDL cholesterol levels below normal levels during the first 
year of the study. Lately, the independent effects of statins on 
CRP are debated.134 In their extensive meta-analysis, Genser 
and colleagues135 found a close correlation between statin-
induced reductions in LDL cholesterol and CRP which has 
not been evident from individual studies. This discrepancy 
could be attributed to the great variability and the non-normal 
distribution of the values of CRP. As long as serum CRP 
originates predominately from the liver and secondly form 
the sites of inflammation, different degrees of inflammation 
could probably stimulate different sites of CRP production. 
If this hypothesis is true, CRP measured in low degrees of 
inflammation, such as in the general population, could origi-
nate from local production in atherosclerotic plaques, while 
CRP measured in higher degrees of inflammation, such as in 
end-stage renal disease patients, could originate predominantly 
from liver production. Statins effects might differ in each situ-
ation, and their effects on the CRP produced by the liver might 
be linked somehow with the inhibition of HMG-CoA reduc-
tase, while peripherally produced CRP might be genuinely 
independent. Unfortunately, in CARE study there has not been 
a separate analysis of the correlation between CRP and lipid 
decrease in those patients with the highest levels of CRP, it is 
however characteristic that these patients enjoyed the maximal 
cardiovascular benefits. However, in PRINCE study such 
a correlation was indeed found in the patients with hsCRP 
values within the highest quartile. Other studies revealed 
several other beneficial effects of statins, most notably their 
immunosuppressant effects in heart transplant recipients. 
These studies have suggested a better transplant outcome 
in patients taking statin therapy136,137 as well as improved 
endothelial function and reduced inflammatory cytokine 
release.138 In renal transplant recipients, some evidence for 
similar beneficial effects of statins on endothelial functions 
has been noted139,140 and, probably, on the rate of acute rejection 
reactions,141 although the later is still debatable.142–144
The effect of serum lipids on monocyte adhesion 
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The monocyte adhesion molecules CD11b145 and CD14 have 
been found to be elevated and l-selectin to be decreased 
(usually, this occurs as a consequence of cell activation) in 
patients with hypercholesterolemia compared with control 
subjects; furthermore, the levels of each of these adhesion 
molecules were found to correlate with those of LDL.146 
Simvastatin was found to correct the levels of each of these 
towards normal. The exposure of normal leukocytes to LDL 
induced changes similar to those in the hypocholesterolemic 
patients. It is important to note that changes in monocyte 
adhesion molecule expression in the patients can be a direct 
consequence of their exposure to increased LDL levels. 
Reversal with statins may therefore be attributable both to 
their hypocholesterolemic effect and to another direct effect 
on the cells unrelated to lipid lowering. Finally, several 
in vivo studies have also investigated the effect of statin 
therapy on the regulation of the fibrinolytic system. Although 
the results are inconsistent, in some studies statins decrease 
PAI-1 plasma levels.147
Conclusions
In recent years several in vitro and in vivo studies have 
provided solid evidence suggesting that statins exert multiple 
vasoprotective effects. Some of them are likely to be indepen-
dent of the lipid-lowering effects of these drugs. However, 
caution is needed when an effect is to be disconnected from 
others, as long as it is now clear that there are multiple inter-
connections between lipid- and nonlipid-lowering pathways 
and the endothelium is the center where many different 
physiologic intercalating pathways converge. Furthermore, 
hypercholesterolemia itself has an inflammatory effect on 
the vascular endothelium and liver.148 To this extent, the 
correlation between different effects of statins appears to be 
like the causality dilemma, “which came first, the chicken 
or the egg?”, and it wouldn’t be surprising if future research 
revealed a correlation of effects which nowadays seem 
independent. Given all the evidence that research has come 
up to, it is now tempting to question the multiple-dispersed 
“pleiotropic” effects of statins in favor of a unifying theory 
that would bind together the pieces of the puzzle.
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